RENE Reneuron Group Plc

TIDMRENE

RNS Number : 9753P

ReNeuron Group plc

06 September 2017

 
 6 September 2017   AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or the "Company")

Result of AGM

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at its Annual General Meeting, held earlier today, were duly passed.

ENQUIRIES:

 
ReNeuron                                                                  +44 (0)20 3819 8400 
Olav Hellebø , Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                                                  +44 (0) 20 7466 5000 
Mark Court, Sophie Cowles, Stephanie Watson 
 
Stifel Nicolaus Europe Limited                                            +44 (0) 20 7710 7600 
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) 
N+1 Singer Advisory LLP                                                   +44 (0) 20 7496 3000 
Mark Taylor (Joint Broker) 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGUNARRBAAKRAR

(END) Dow Jones Newswires

September 06, 2017 06:15 ET (10:15 GMT)

Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024

Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024